CLERICO, Marinella
CLERICO, Marinella
SCIENZE CLINICHE E BIOLOGICHE
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b
2006-01-01 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b
2006-01-01 A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes
2006-01-01 M. CLERICO; F. FAGGIANO; J. PALACE; M. TINTOR; G. RICE; L. DURELLI
A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis
2006-01-01 M. CLERICO; M. TINTORE' SUBIRANA; J. PALACE; G. RICE; F. FAGGIANO; L. DURELLI
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study.
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI
A new computational workflow to guide personalized drug therapy
2023-01-01 Pernice, Simone; Maglione, Alessandro; Tortarolo, Dora; Sirovich, Roberta; Clerico, Marinella; Rolla, Simona; Beccuti, Marco; Cordero, Francesca
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients.
2011-01-01 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
2006-01-01 Durelli, Luca; Barbero, Pierangelo; Clerico, Marinella
A Real-Life Study of Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity
2018-01-01 Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, GT; Cordioli, C; Rasia, S; Clerico, M; Fenu, G; Cocco, E; Frau, J
A real-world study of Alemtuzumab in a cohort of Italian patients
2019-01-01 Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
2017-01-01 Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T
Adherence to interferon-beta treatment and results of therapy switching
2007-01-01 Clerico, Marinella; Barbero, Pierangelo; Contessa, Giulia; Ferrero, Cinzia; Durelli, Luca
Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review
2023-01-01 Capasso, Nicola; Virgilio, Eleonora; Covelli, Antonio; Giovannini, Beatrice; Foschi, Matteo; Montini, Federico; Nasello, Martina; Nilo, Annacarmen; Prestipino, Elio; Schirò, Giuseppe; Sperandei, Silvia; Clerico, Marinella; Lanzillo, Roberta
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
2016-01-01 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation
2016-01-01 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
2016-01-01 De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study
2018-01-01 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
ALTERATIONS IN GUT MICROBIOME COMPOSITION ARE ASSOCIATED WITH THE ONSET AND COURSE OF MULTIPLE SCLEROSIS: AN ITALIAN COHORT STUDY
2023-01-01 Rachele Rosso, Alessandro Maglione, Marinella Clerico, Simona Rolla
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study
2014-01-01 A. Chiò;A. Calvo;G. Bovio;A. Canosa;D. Bertuzzo;F. Galmozzi;P. Cugnasco;M. Clerico;S. De Mercanti;E. Bersano;S. Cammarosano;A. Ilardi;U. Manera;C. Moglia;R. Sideri;K. Marinou;E. Bottacchi;F. Pisano;R. Cantello;L. Mazzini;G. Mora; Piemonte;V. d. Register
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b | 2006 | A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b | 2006 | A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes | 2006 | M. CLERICO; F. FAGGIANO; J. PALACE; M. TINTOR; G. RICE; L. DURELLI | |
| A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis | 2006 | M. CLERICO; M. TINTORE' SUBIRANA; J. PALACE; G. RICE; F. FAGGIANO; L. DURELLI | |
| A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI | |
| A new computational workflow to guide personalized drug therapy | 2023 | Pernice, Simone; Maglione, Alessandro; Tortarolo, Dora; Sirovich, Roberta; Clerico, Marinella; Rolla, Simona; Beccuti, Marco; Cordero, Francesca | |
| A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. | 2011 | Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli | |
| A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis | 2006 | Durelli, Luca; Barbero, Pierangelo; Clerico, Marinella | |
| A Real-Life Study of Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity | 2018 | Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, GT; Cordioli, C; Rasia, S; Clerico, M; Fenu, G; Cocco, E; Frau, J | |
| A real-world study of Alemtuzumab in a cohort of Italian patients | 2019 | Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A | |
| Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab | 2017 | Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T | |
| Adherence to interferon-beta treatment and results of therapy switching | 2007 | Clerico, Marinella; Barbero, Pierangelo; Contessa, Giulia; Ferrero, Cinzia; Durelli, Luca | |
| Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review | 2023 | Capasso, Nicola; Virgilio, Eleonora; Covelli, Antonio; Giovannini, Beatrice; Foschi, Matteo; Montini, Federico; Nasello, Martina; Nilo, Annacarmen; Prestipino, Elio; Schirò, Giuseppe; Sperandei, Silvia; Clerico, Marinella; Lanzillo, Roberta | |
| Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months | 2016 | Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M | |
| Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation | 2016 | Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M | |
| Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months | 2016 | De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella | |
| Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L. | |
| Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study | 2018 | Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M | |
| ALTERATIONS IN GUT MICROBIOME COMPOSITION ARE ASSOCIATED WITH THE ONSET AND COURSE OF MULTIPLE SCLEROSIS: AN ITALIAN COHORT STUDY | 2023 | Rachele Rosso, Alessandro Maglione, Marinella Clerico, Simona Rolla | |
| Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study | 2014 | A. Chiò;A. Calvo;G. Bovio;A. Canosa;D. Bertuzzo;F. Galmozzi;P. Cugnasco;M. Clerico;S. De Mercanti;E. Bersano;S. Cammarosano;A. Ilardi;U. Manera;C. Moglia;R. Sideri;K. Marinou;E. Bottacchi;F. Pisano;R. Cantello;L. Mazzini;G. Mora; Piemonte;V. d. Register |